BTTX Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EST
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.86
Previous CloseN/A
Volume65.57K
Average Volume (3M)0.00
Market Cap
$5.43K
Enterprise Value$21.80
Total Cash (Recent Filing)$6.60M
Total Debt (Recent Filing)$14.31M
Price to Earnings (P/E)―
Beta151.59
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,352,497
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)-29.09
Price to Sales (P/S)0.00
P/FCF Ratio-0.87
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Better Therapeutics News
BTTX FAQ
What was Better Therapeutics, Inc.’s price range in the past 12 months?
Better Therapeutics, Inc. lowest stock price was <$0.01 and its highest was $0.85 in the past 12 months.
What is Better Therapeutics, Inc.’s market cap?
Better Therapeutics, Inc.’s market cap is $5.43K.
When is Better Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Better Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Better Therapeutics, Inc. overvalued?
According to Wall Street analysts Better Therapeutics, Inc.’s price is currently Overvalued.
Does Better Therapeutics, Inc. pay dividends?
Better Therapeutics, Inc. does not currently pay dividends.
What is Better Therapeutics, Inc.’s EPS estimate?
Better Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Better Therapeutics, Inc. have?
Better Therapeutics, Inc. has 54,352,497 shares outstanding.
What happened to Better Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Better Therapeutics, Inc.?
Currently, no hedge funds are holding shares in BTTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Better Therapeutics, Inc.
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis ,and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Scinai Immunotherapeutics
―
MSP Recovery
―
Dermata Therapeutics
―
Bluejay Diagnostics
―
CDT Equity
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors